ArticleFrontiers in immunology2026
Gut microbiota and serum metabolome in children with human metapneumovirus infection.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the alterations in gut microbiota structure and serum metabolic profiles of children with human metapneumovirus (hMPV) infection using 16S rRNA high-throughput sequencing and liquid chromatography-mass spectrometry (LC-MS)-based untargeted metabolomics. Through integrated multi-omics analysis, we aim to explore the correlation between gut microbiota dysbiosis and host metabolic disorder, provide preliminary evidence for potential intervention targets, and offer primary clues for the development of preventive and therapeutic strategies including probiotic supplementation and metabolic pathway regulation. Methods: This study enrolled 42 children with hMPV infection and 12 healthy controls. Fecal samples were collected for gut microbiota analysis using 16S rRNA gene sequencing, and serum samples were obtained for metabolomic profiling via LC-MS. Various bioinformatics approaches were applied for independent analysis of microbiome and metabolome data, followed by integrated multi-omics analysis. Results: The microbial community structure of the hMPV-infected group was clearly separated from that of the healthy control group. Opportunistic pathogens such as Finegoldia, Anaerococcus, and Peptoniphilus were enriched, while beneficial commensals including Bifidobacterium, Blautia, and Faecalibacterium were reduced. Serum metabolic profiles showed global divergence between the two groups, with 558 upregulated and 213 downregulated metabolites identified. Using a VIP threshold >1.5, 24 core differential metabolites were ultimately selected. KEGG enrichment and MetPA topological analyses revealed that these differential metabolites were mainly enriched in pathways including glycerophospholipid metabolism, nucleotide metabolism, alpha-linolenic acid metabolism, and arachidonic acid metabolism. Correlation analysis showed that beneficial commensals with reduced abundance in the infected group, such as Bifidobacterium and Blautia, were positively correlated with anti-inflammatory and barrier-protective metabolites (e.g., alpha-linolenic acid, 11,12-DiHETrE, GPCho(20:4/14:0)), and negatively correlated with pro-inflammatory lipid mediators (e.g., 12,13-DiHOME, 9-OxoODE, vernolic acid). Conclusion: This study indicated that hMPV infection might be associated with intestinal microecological imbalance and serum metabolic disturbances in children. The screened core differential metabolites hold the potential for further evaluation of their diagnostic value. Significant correlations exist between gut microbiota alterations and serum metabolic disorders, providing preliminary clues for the future development of preventive and therapeutic strategies targeting gut microbiota or metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.